Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
June 09 2022 - 7:00AM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing nutritional cognitive
behavioral therapy (nCBT) to address the root causes of
cardiometabolic diseases, today announced that it will participate
in a webinar on Unlocking the Value of Digital Prescription
Therapeutics hosted by Cowen to discuss the recently released
promising pivotal clinical trial data for BT-001, its digital
therapeutic platform for type 2 diabetes, and how BT-001 may be
used in the current type 2 diabetes treatment paradigm.
WHEN: Thursday, June 16, 2022 at 10:00 a.m. ET
WHAT: The Unlocking the Value of Digital Prescription
Therapeutics webinar will be hosted by Charles Rhyee, an equity
research analyst with Cowen, and will provide an opportunity to
review the primary endpoint results from the company’s pivotal
clinical trial for BT-001 and discuss how BT-001 may be used in the
current type 2 diabetes treatment paradigm. Released earlier this
year, the pivotal clinical trial demonstrated significant reduction
in A1c levels that surpassed results seen in patients using
pharmaceutical solutions alone.
WHO:
- Mark Berman, MD, Chief Medical Officer, Better
Therapeutics
- Prapti Mehta, MD, Chief Behavioral Scientist, Better
Therapeutics
- Marc Bonaca, MD, MPH, Director of Vascular Research at Colorado
Prevention Center, Professor of Medicine at University of Colorado
School of Medicine
WHERE: Cowen hosted events are intended for prospective
and existing Cowen clients only. To listen to the live event,
please contact your Cowen representative.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220609005141/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Sep 2023 to Sep 2024